Amgen presents positive first Phase 2 data for AMG 334 in the prevention of episodic migraine
18 May 2015 | By Victoria White
Amgen has announced the first results from its global Phase 2 study evaluating the efficacy and safety of AMG 334 for the prevention of episodic migraine...